| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Malignant Lymphomas |
From the Centre Hospitalier Universitaire (CHU) Pontchaillou, Rennes, France (SV, MB); CHU Edouard Herriot, Lyon, France (MM); CHU Saint-Louis, Paris, France (RP, LA, GS); CHU Purpan, Toulouse, France (MA); Institut Paoli-Calmettes, Marseille, France (DB); CHU du Haut-Levêque, Bordeaux, France (RT, NM); CHU Michallon, Grenoble, France (FG); CHU Archet, Nice, France (J-PC); CHU Hôtel Dieu, Nantes, France (PC); CHU Huriez, Lille, France (TF); CHU d’Angers, Angers, France (NI); CHU La Miletrie, Poitiers, France (MR); Centre Henri-Becquerel, Rouen, France (HT); CHU de la Pitié Salpetrière, Paris, France (J-PV); CHU Henri Mondor, Créteil, France (MK); Institut Gustave Roussy, Villejuif, France (J-HB); CHU de Brabois, Nancy, France (PB); CHU J. Minjoz, Besançon, France (ED); CHU Hautepierre, Strasbourg, France (BL)
Correspondence: Stéphane Vigouroux, MD, Service d’Hématologie Clinique, CHU Pontchaillou, 2 rue Henri Le Guilloux, 35000 Rennes, France. E-mail: vigouroux.st{at}wanadoo.fr
Background and Objectives: High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven to be a successful treatment for low-grade lymphoma (LGL), but is associated with considerable transplant-related mortality (TRM). In an effort to reduce toxic mortality while maintaining the graft-versus-leukemia effect, allogeneic SCT has been combined with a reduced-intensity conditioning (RIC) regimen. The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT.
Design and Methods: This retrospective multicenter study included 73 patients with relapsed or refractory LGL allografted after a RIC regimen between 1998 and 2005 whose data were recorded in a French registry.
Results: Patients received a median of three lines of therapy prior to RIC allogeneic SCT. The most widely used conditioning regimens were fludarabine + busulfan + antithymocyte globulin (n=43) and fludarabine + total body irradiation (n=21). Prior to allografting, patients were in complete response (CR; n=21), partial response (PR; n=33) or had chemoresistant disease (n=19). The median follow-up was 37 months (range, 16 to 77 months). In patients in CR, PR and chemoresistant disease, the 3-year overall survival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival rates were 66%, 52% and 32%, respectively. The 3-year cumulative incidences of TRM were 32%, 28% and 63%, respectively. The incidence of relapse was 9.6%.
Interpretation and Conclusions: Although associated with significant TRM, RIC allogeneic SCT in advanced chemosensitive disease leads to long-term survival.
Key words: RIC allogeneic transplantation, low-grade lymphoma.
Related Article
Haematologica 2007 92: 580-582.
This article has been cited by other articles:
|
|
 |
|
  I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood, June 15, 2008; 111(12): 5530 - 5536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Farina and P. Corradini Current role of allogeneic stem cell transplantation in follicular lymphoma Haematologica, May 1, 2007; 92(5): 580 - 582. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
